Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 21 | 2023 | 157 | 10.480 |
Why?
|
| Quinolones | 11 | 2022 | 35 | 6.250 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 14 | 2023 | 35 | 5.430 |
Why?
|
| Aminophenols | 12 | 2022 | 15 | 5.210 |
Why?
|
| Benzodioxoles | 6 | 2022 | 56 | 1.940 |
Why?
|
| Nasal Mucosa | 3 | 2021 | 22 | 1.690 |
Why?
|
| Pyrazoles | 3 | 2022 | 110 | 1.540 |
Why?
|
| Pyrrolidines | 3 | 2022 | 88 | 1.500 |
Why?
|
| Pyridines | 3 | 2022 | 137 | 1.500 |
Why?
|
| Indoles | 3 | 2022 | 289 | 1.350 |
Why?
|
| Organoids | 3 | 2021 | 41 | 1.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 128 | 1.170 |
Why?
|
| Mutation | 8 | 2023 | 1504 | 1.070 |
Why?
|
| Epithelial Cells | 5 | 2023 | 255 | 1.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 52 | 0.770 |
Why?
|
| Genetic Therapy | 1 | 2020 | 121 | 0.700 |
Why?
|
| Liver Transplantation | 1 | 2021 | 159 | 0.680 |
Why?
|
| Rhodospirillaceae | 1 | 2018 | 1 | 0.660 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 26 | 0.630 |
Why?
|
| Rifampin | 1 | 2018 | 57 | 0.620 |
Why?
|
| Staphylococcal Infections | 2 | 2018 | 302 | 0.620 |
Why?
|
| Humans | 26 | 2023 | 54304 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 825 | 0.510 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1300 | 0.480 |
Why?
|
| Ion Transport | 2 | 2021 | 17 | 0.410 |
Why?
|
| Child | 8 | 2023 | 7372 | 0.370 |
Why?
|
| Genotype | 2 | 2023 | 600 | 0.370 |
Why?
|
| Pseudomonas Infections | 2 | 2020 | 54 | 0.350 |
Why?
|
| Adolescent | 6 | 2023 | 6896 | 0.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 88 | 0.300 |
Why?
|
| Oxygen | 1 | 2008 | 361 | 0.260 |
Why?
|
| Quality of Life | 3 | 2023 | 922 | 0.260 |
Why?
|
| Adult | 5 | 2021 | 14189 | 0.240 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 44 | 0.230 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2020 | 86 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1064 | 0.220 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 55 | 0.220 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 89 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2023 | 132 | 0.210 |
Why?
|
| Forced Expiratory Volume | 2 | 2020 | 47 | 0.210 |
Why?
|
| Nose | 1 | 2021 | 42 | 0.200 |
Why?
|
| Mutant Proteins | 1 | 2020 | 41 | 0.190 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 98 | 0.190 |
Why?
|
| Sweat | 1 | 2020 | 7 | 0.190 |
Why?
|
| Female | 6 | 2021 | 28457 | 0.180 |
Why?
|
| Chlorides | 1 | 2020 | 58 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 426 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 248 | 0.170 |
Why?
|
| Asthma | 1 | 2023 | 293 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2020 | 398 | 0.160 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2018 | 6 | 0.160 |
Why?
|
| Amikacin | 1 | 2018 | 19 | 0.160 |
Why?
|
| Clindamycin | 1 | 2018 | 15 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2018 | 28 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 742 | 0.160 |
Why?
|
| Phenotype | 2 | 2020 | 820 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2018 | 43 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2017 | 16 | 0.160 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1229 | 0.150 |
Why?
|
| Body Weight | 1 | 2020 | 574 | 0.150 |
Why?
|
| Drug Combinations | 1 | 2017 | 128 | 0.150 |
Why?
|
| Particle Size | 1 | 2017 | 87 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 82 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2018 | 206 | 0.150 |
Why?
|
| Virulence | 1 | 2018 | 196 | 0.150 |
Why?
|
| Biological Transport | 1 | 2017 | 195 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2018 | 81 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2018 | 153 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 805 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2018 | 5609 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 457 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2018 | 133 | 0.140 |
Why?
|
| Male | 5 | 2020 | 27335 | 0.140 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1737 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2020 | 2604 | 0.120 |
Why?
|
| Lung | 3 | 2023 | 507 | 0.120 |
Why?
|
| United States | 2 | 2020 | 5204 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2389 | 0.110 |
Why?
|
| Young Adult | 2 | 2020 | 4313 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2018 | 6462 | 0.080 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 52 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 87 | 0.080 |
Why?
|
| Cell Line | 2 | 2008 | 1152 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2008 | 388 | 0.070 |
Why?
|
| Codon, Nonsense | 1 | 2023 | 29 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 23 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2003 | 22 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 60 | 0.060 |
Why?
|
| Smoke | 1 | 2023 | 21 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 2002 | 0.050 |
Why?
|
| Transaminases | 1 | 2022 | 14 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 243 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 131 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 386 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 248 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2003 | 622 | 0.040 |
Why?
|
| Mice | 2 | 2008 | 6428 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 52 | 0.040 |
Why?
|
| Respiratory System | 1 | 2018 | 28 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 245 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 1547 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 766 | 0.040 |
Why?
|
| Cross Infection | 1 | 2018 | 109 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 915 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2018 | 187 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 705 | 0.040 |
Why?
|
| Animals | 3 | 2008 | 14402 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2018 | 232 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 111 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 1200 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 683 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 683 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 363 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3832 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 4161 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 39 | 0.020 |
Why?
|
| Biotinylation | 1 | 2004 | 23 | 0.020 |
Why?
|
| COS Cells | 1 | 2004 | 78 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 41 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2003 | 8 | 0.010 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2003 | 9 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 75 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 112 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 20 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 108 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 226 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 196 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 291 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 131 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 399 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 123 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 115 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 279 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 120 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 200 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 674 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 692 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 684 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 509 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 868 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 3207 | 0.010 |
Why?
|